DUTCH Weight Control in Atrial Fibrillation Study
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorRijnstate Hospital
About this trial
Quantify the effect of an innovative weight loss management on rhythm control.
Eligibility criteria
Qualifiers
Symptomatic, first detected (at maximum 6 months prior to enrollment) persistent AF -
Age ≥ 18
BMI ≥ 30 kg/m2, or
BMI ≥27 kg/m2 with the presence of at least one weight related comorbidity (treated or untreated, e.g. hypertension, dyslipidaemia, obstructive sleep apnea, cardiovascular disease)
Disqualifiers
Permanent AF
Secondary AF, i.e. due to thyrotoxicosis, infection (e.g. pneumonia) or post-(cardiothoracic) surgery
Current or previous treatment with amiodaron
HbA1c ≥ 48 mmol/L, <3 months prior to randomization
Trial design
Treatments tested in this trial
- Semaglutide 3.2 MG/ML
- Placebo
Treatment groups
280 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov